Secura’s Copiktra: Trial Design, Shifting Standard Of Care Could Spell The End For Third-Line CLL/SLL

 
• By Sue Sutter
Changing landscape
The changing therapeutic landscape in CLL/SLL has influenced the FDA's reconsideration of Copiktra's benefit-risk profile. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers